NASDAQ | TSX: ACB

纳斯达克 | 多伦多证券交易所：ACB

EDMONTON, AB

埃德蒙顿，阿尔伯塔省

,

，

April 15, 2026

2026年4月15日

/PRNewswire/ - Aurora Cannabis Inc. (the

/PRNewswire/ - Aurora Cannabis Inc.（

'Company'

'公司'

or

或

'Aurora'

'极光'

) (NASDAQ:

) （纳斯达克：

ACB

ACB

) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce it has acquired Safari Flower Company, an established EU GMP certified cannabis cultivator and manufacturer. Aggregate consideration is valued at $26.5 million, subject to customary adjustments, and inclusive of a cash payment of $2 million that is contingent on satisfaction of certain conditions (the '.

) (TSX: ACB)，这家加拿大领先的全球医用大麻公司，很高兴地宣布已收购了Safari Flower Company，这是一家已建立的欧盟GMP认证的大麻种植商和制造商。总对价估值为2650万美元，视常规调整而定，并包括一笔200万美元的现金支付，该款项的支付取决于某些条件的满足（“）。

Transaction

事务

').

`').``

'The acquisition of Safari Flower Company marks an important milestone for Aurora as we continue to purposefully invest in expanding our EU GMP capacity to support the rapidly growing international medical cannabis market. We intend to leverage our extensive plant science and operational expertise to increase the supply of high quality, EU GMP manufactured flower that further enhances our leadership in these expanding, high margin and highly regulated markets.

“收购Safari花卉公司对极光来说是一个重要的里程碑，因为我们继续有目的地投资于扩大我们的欧盟GMP产能，以支持快速增长的国际医用大麻市场。我们打算利用我们在植物科学和运营方面的广泛专业知识，增加高质量、欧盟GMP认证的大麻花的供应，进一步增强我们在这些不断扩展的高利润和高度监管市场中的领导地位。”

An enhanced supply chain will enable us to capture greater international market share while delivering superior quality and value to our most respected patients worldwide,' said Miguel Martin, Executive Chairman and Chief Executive Officer for Aurora..

米格尔·马丁表示：“一个增强的供应链将使我们能够占据更大的国际市场份额，同时为我们在全球最受尊敬的患者提供更优质的服务和价值。”

Strategic Rationale

战略理由

Safari Flower Company's 59,000 square foot, purpose-built EU GMP certified indoor cultivation and manufacturing facility in Ontario, Canada will provide the Company with incremental capacity that is closely aligned with its existing cultivation and manufacturing sites.

加拿大安大略省 Safari Flower 公司59,000平方英尺的专用欧盟GMP认证室内种植和生产设施，将为公司提供与其现有种植和生产基地紧密契合的增量产能。

The increased capacity will be used to supply EU GMP flower to Aurora's key international markets, including Germany, Australia, Poland, and the UK, and support further market expansion.

增加的产能将用于向极光公司在德国、澳大利亚、波兰和英国等主要国际市场供应符合欧盟GMP标准的大麻花，并支持进一步的市场扩张。

This transaction is expected to deliver positive Adjusted EBITDA contributions in fiscal year 2027, with incremental benefits in fiscal year 2028 and beyond as these assets are optimised within the Company's supply network.

预计这项交易将在2027财年带来正的调整后息税折旧摊销前利润（EBITDA）贡献，并在2028财年及以后随着这些资产在公司供应链网络中得到优化而产生增量效益。

Aurora intends to leverage its plant science and operational expertise to realize operational efficiencies, improve cultivation yields and support commercial execution in the high margin international markets.

极光公司打算利用其植物科学和运营专业知识，实现运营效率，提高种植产量，并支持在高利润的国际市场上的商业执行。

Transaction Details

交易明细

Aurora, through a wholly-owned subsidiary, indirectly purchased 100% of the shares of 9869247 Canada Limited ('

极光通过其全资子公司间接购买了9869247加拿大有限公司100%的股份。

Safari Flower Company

萨法里花卉公司

') for aggregate consideration valued at $26.5 million, inclusive of a cash payment of $2 million that is contingent on satisfaction of certain conditions. As consideration on closing, Aurora (i) issued the selling shareholder 2,417,180 common shares; and (ii) paid the selling shareholder $15 million in cash, subject to customary adjustments post-closing..

`)，总对价为2650万美元，其中包括一笔200万美元的现金支付，该款项取决于某些条件的满足。作为交割时的对价，极光公司（i）向卖方股东发行了2,417,180股普通股；（ii）向卖方股东支付了1500万美元现金，该金额需根据交割后的常规调整进行调整。`

About Aurora

关于极光

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach.

极光是全球医用大麻领域的领导者，致力于通过科学专业知识、卓越表现以及对患者护理的深切承诺来改善生活。极光服务于加拿大、欧洲、澳大利亚和新西兰的医用和消费市场，聚焦高利润机会，并采用以医疗为先的战略方法。

Aurora's portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty's® and Whistler Medical Marijuana Co.®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™..

Aurora旗下值得信赖的领先品牌组合包括Aurora®、MedReleaf®、Pedanios®、IndiMed™、San Raf®、Tasty's®和Whistler Medical Marijuana Co.®。凭借在加拿大和德国的世界级GMP认证生产设施，以及一支行业领先的专家团队，Aurora继续扩展其全球足迹，并以开启世界大麻之门™为目标，持续提供始终如一的高品质大麻产品。

Learn more at

了解更多请访问

www.auroramj.com

www.auroramj.com

and follow us on X and LinkedIn.

关注我们在X和LinkedIn上的账号。

Aurora's common shares trade on the NASDAQ and TSX under the symbol 'ACB'.

极光的普通股在纳斯达克和多伦多证券交易所交易，股票代码为“ACB”。

Forward Looking Information

前瞻性信息

This news release includes statements containing certain 'forward-looking information' within the meaning of applicable securities law ('

本新闻稿包含某些适用证券法意义上的“前瞻性信息”的声明（

forward-looking statements

前瞻性声明

'). Forward-looking statements are frequently characterized by words such as 'plan', 'continue', 'expect', 'project', 'intend', 'believe', 'anticipate', 'estimate', 'may', 'will', 'potential', 'proposed' and other similar words, or statements that certain events or conditions 'may' or 'will' occur. Forward-looking statements made in this news release include statements regarding the Transaction, including, but not limited to:.

`). 前瞻性声明通常以诸如“计划”、“继续”、“预期”、“项目”、“意图”、“相信”、“预计”、“估计”、“可能”、“将”、“潜在”、“建议”等词语以及其他类似词语为特征，或包含某些事件或条件“可能”或“将会”发生的陈述。本新闻稿中的前瞻性声明包括关于此次交易的声明，包括但不限于：。`

the impact of the Transaction on the Company's financial performance and the synergies, revenue, positive cash flow and positive Adjusted EBITDA expected to be realized as a result of the Transaction

交易对公司财务业绩的影响，以及交易预计带来的协同效应、收入、正现金流和正调整后息税折旧摊销前利润（EBITDA）

.

。

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, current and expected market trends, product supply and demand, financial performance, and ongoing global regulatory developments, as well as publicly available information from governmental sources, market research and industry , and assumptions based on data and knowledge of this industry which the Company believes to be reasonable.

这些前瞻性陈述仅为预测。本新闻稿中包含的前瞻性信息或声明是基于管理层认为合理的假设而制定的。制定前瞻性声明时涉及的重要因素或假设包括但不限于：当前和预期的市场趋势、产品供需、财务表现、持续的全球监管发展，以及来自政府来源、市场研究和行业的公开信息，以及公司认为合理的基于该行业数据和知识的假设。

Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements.

前瞻性声明受多种风险、不确定性及其他因素的影响，管理层认为这些因素在当前情况下是相关且合理的，可能导致实际事件、结果、活动水平、业绩、前景、机会或成就与前瞻性声明中预测的内容存在重大差异。

These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acqui.

这些风险包括但不限于：从加拿大进口到美国的商品可能面临的新关税或增加关税的幅度和持续时间；保留关键人员的能力、继续投资以支持增长的基础设施的能力、以可接受的条件获得融资的能力、我们产品的持续质量、客户体验与留存、第三方政府和非政府消费者销售渠道的开发、管理层对加拿大以及公司出口地区的消费者需求的估计、对未来业绩和支出的预期、成功整合已收购业务和运营的风险（针对本次交易以及更普遍的未来收购）。

AIF

人工智能基金

') and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at

') 并已提交给加拿大证券监管机构，可在SEDAR+上公司的发行人档案中查阅。

www.sedarplus.com

www.sedarplus.com

and filed with and available on the SEC's website at

并向美国证券交易委员会提交，且可在其网站上查阅，网址为

www.sec.gov

www.sec.gov

. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information.

公司警告说，AIF中描述的风险、不确定性和其他因素的列表并不详尽，其他因素也可能对其结果产生不利影响。读者在评估前瞻性声明时，务必要仔细考虑这些风险、不确定性和假设，并被提醒不要过度依赖此类信息。

The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law..

公司没有任何义务，也明确否认有任何意图或义务更新或修改任何前瞻性声明，无论是否由于新信息、未来事件或其他原因，除非适用的证券法明确要求。

Non-GAAP Measures

非公认会计原则指标

This news release contains reference to certain financial performance measures that are not recognized or defined under IFRS (termed 'Non-GAAP Measures'). As a result, this data may not be comparable to data presented by other licensed producers of cannabis and cannabis companies. Non-GAAP Measures in this news release include, but are not limited to, .

本新闻稿包含对某些财务绩效指标的引用，这些指标在国际财务报告准则（IFRS）下未被认可或定义（称为“非GAAP指标”）。因此，这些数据可能无法与其他大麻生产商和大麻公司的数据进行比较。本新闻稿中的非GAAP指标包括但不限于。

Adjusted EBITDA

调整后的息税折旧摊销前利润

. Non-GAAP Measures should be considered together with other data prepared in accordance with IFRS to enable investors to evaluate the Company's operating results, underlying performance and prospects in a manner similar to Aurora's management. Accordingly, these non-GAAP Measures are intended to provide additional information and to assist management and investors in assessing financial performance and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.

非公认会计原则指标应与根据国际财务报告准则编制的其他数据一起考虑，以使投资者能够以类似于极光管理层的方式评估公司的经营结果、基本业绩和前景。因此，这些非公认会计原则指标旨在提供更多信息，并帮助管理层和投资者评估财务业绩，不应单独考虑或作为根据国际财务报告准则编制的业绩指标的替代品。

The information included under the heading 'Cautionary Statement Regarding Certain Non-GAAP Performance Measures' in the Company's management's discussion and analysis for the three and nine months ended December 31, 3025, and 2025 (the '.

公司管理层对截至3025年12月31日和2025年的三个月及九个月的讨论与分析中，在“关于某些非GAAP绩效指标的警示性声明”标题下包含的信息（'。

MD&A

管理层讨论与分析

') is incorporated by reference into this news release. The MD&A is available on the Company's issuer profile on SEDAR+ at

“）通过引用并入本新闻稿。MD&A可在SEDAR+上公司的发行人档案中查阅，网址为”

www.sedarplus.com

www.sedarplus.com

.

。

SOURCE Aurora Cannabis Inc.

来源：极光大麻公司

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示